Robert H. Lenox, M.D., President, RHL BioPharmaceutical Consulting, LLC, Adjunct Professor of Psychiatry, University of Pennsylvania School of Medicine, will be talking on "Lithium targeted Pathways in Brain: A Road from Academia to Pharma" on Friday, January 22, 2010 at 12 p.m. in the Bush Center Conference Room on the University of New England's Biddeford Campus.

The lecture, sponsored by UNE's Center for Excellence in the Neurosciences, is free and open to the public. Lunch will be provided.

Dr. Lenox has had a distinguished academic research and teaching career for over 25 years as a respected psychiatrist and neuroscientist with continuous NIH grant funding and more than 150 peer-reviewed publications, as well as reviews and book chapters, in the fields of molecular neuropharmacology and clinical psychopharmacology. He is also the recipient of numerous prestigious awards and honors that recognize his contributions to medicine. He holds a Bachelor of Science degree in Biochemistry from MIT, a medical degree from University of Vermont College of Medicine and a Masters of Arts (Honours) from University of Pennsylvania.

Dr. Lenox is currently providing CNS drug discovery and development consultation to Academia, Biotech and Venture Capital companies. Until recently he served as Vice President and Worldwide Head of Central Nervous System Drug Discovery for Sanofi- Aventis Pharmaceuticals, with responsibilities for setting strategy and leading CNS drug discovery from target identification, lead discovery and candidate profiling, with oversight for preclinical/phase l and ll development for all psychiatry and neurology programs. Prior to entering the pharmaceutical industry in 2001, Dr. Lenox held an endowed tenured faculty position as the Karl and Linda Rickels Professor of Psychiatry, Pharmacology and Neuroscience and Vice Chairman for Research Development in the Department of Psychiatry at the University of Pennsylvania School of Medicine, where he is currently Adjunct Professor of Psychiatry. Dr. Lenox was Founder and Head of Neuroscience Research and Clinical Psychopharmacology Program in the Department of Psychiatry at the University of Vermont College of Medicine, where he also served as Interim-Chairman.